{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:56:13Z","timestamp":1789480573617,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100017239","name":"BeiGene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s12325-022-02238-7","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T04:02:29Z","timestamp":1658980949000},"page":"4250-4265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Zanubrutinib Monotherapy for Na\u00efve and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies"],"prefix":"10.1007","volume":"39","author":[{"given":"Wei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenmiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9931-4055","authenticated-orcid":false,"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"2238_CR1","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","volume":"118","author":"FK Stevenson","year":"2011","unstructured":"Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118:4313\u201320.","journal-title":"Blood"},{"key":"2238_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","volume":"23","author":"CU Niemann","year":"2013","unstructured":"Niemann CU, Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol. 2013;23:410\u201321.","journal-title":"Semin Cancer Biol"},{"key":"2238_CR3","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","volume":"123","author":"SE Herman","year":"2014","unstructured":"Herman SE, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-\u03baB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123:3286\u201395.","journal-title":"Blood"},{"key":"2238_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","volume":"119","author":"S Ponader","year":"2012","unstructured":"Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182\u20139.","journal-title":"Blood"},{"key":"2238_CR5","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","volume":"119","author":"MF de Rooij","year":"2012","unstructured":"de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119:2590\u20134.","journal-title":"Blood"},{"key":"2238_CR6","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.2013.53.1046","volume":"32","author":"S Ponader","year":"2014","unstructured":"Ponader S, Burger JA. Bruton\u2019s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. 2014;32:1830\u20139.","journal-title":"J Clin Oncol"},{"key":"2238_CR7","unstructured":"Hillmen P, Eichhorst B, Brown J, et al., editors. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. In: Proceedings of the 2021 European hematology association virtual congress; 2021."},{"key":"2238_CR8","unstructured":"NMPA. Zanubrutinib Label in CDE (CXHS2000037). https:\/\/www.cde.org.cn\/main\/xxgk\/postmarketpage?acceptidCODE=5b25b17659c2ce6026869f57909e2053."},{"key":"2238_CR9","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2238_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Trotman J. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134:851\u20139.","journal-title":"Blood"},{"key":"2238_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","volume":"13","author":"W Xu","year":"2020","unstructured":"Xu W, Yang S, Zhou K, et al. Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol. 2020;13:48.","journal-title":"J Hematol Oncol"},{"key":"2238_CR12","volume-title":"BGB-3111, a highly specific BTK inhibitor, is well tolerated and highly active in Chinese patients with relapsed\/refractory B-cell malignancies: initial report of a phase 1 trial in China","author":"J Zhu","year":"2017","unstructured":"Zhu J, Li J, Zhou J, et al. BGB-3111, a highly specific BTK inhibitor, is well tolerated and highly active in Chinese patients with relapsed\/refractory B-cell malignancies: initial report of a phase 1 trial in China. Washington DC: American Society of Hematology; 2017."},{"key":"2238_CR13","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1080\/10428194.2021.1929961","volume":"62","author":"YC Ou","year":"2021","unstructured":"Ou YC, Tang Z, Novotny W, et al. Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma. Leuk Lymphoma. 2021;62:2612\u201324.","journal-title":"Leuk Lymphoma"},{"key":"2238_CR14","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446\u201356.","journal-title":"Blood"},{"key":"2238_CR15","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"2238_CR16","unstructured":"Yang D, Dalton JE, editors. A unified approach to measuring the effect size between two groups using SAS\u00ae. SAS global forum; 2012."},{"key":"2238_CR17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38:1228\u201334.","journal-title":"Commun Stat Simul Comput"},{"key":"2238_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13045-021-01174-3","volume":"14","author":"K Zhou","year":"2021","unstructured":"Zhou K, Zou D, Zhou J, et al. Zanubrutinib monotherapy in relapsed\/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. J Hematol Oncol. 2021;14:167.","journal-title":"J Hematol Oncol"},{"key":"2238_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1200\/JCO.20.00979","volume":"39","author":"IE Ahn","year":"2021","unstructured":"Ahn IE, Tian X. Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model. J Clin Oncol. 2021;39:576\u201385.","journal-title":"J Clin Oncol"},{"key":"2238_CR20","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ajh.25436","volume":"94","author":"SM O'Brien","year":"2019","unstructured":"O\u2019Brien SM, Byrd JC, Hillmen P, et al. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019;94:554\u201362.","journal-title":"Am J Hematol"},{"key":"2238_CR21","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","volume":"127","author":"F Nadeu","year":"2016","unstructured":"Nadeu F, Delgado J, Royo C, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016;127:2122\u201330.","journal-title":"Blood"},{"key":"2238_CR22","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","volume":"131","author":"IE Ahn","year":"2018","unstructured":"Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131:2357\u201366.","journal-title":"Blood"},{"key":"2238_CR23","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","volume":"131","author":"S O'Brien","year":"2018","unstructured":"O\u2019Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131:1910\u20139.","journal-title":"Blood"},{"key":"2238_CR24","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","volume":"133","author":"DM Stephens","year":"2019","unstructured":"Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133:1298\u2013307.","journal-title":"Blood"},{"key":"2238_CR25","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam CS, Opat S, D\u2019Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood. 2020;136:2038\u201350.","journal-title":"Blood"},{"key":"2238_CR26","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441\u201352.","journal-title":"J Clin Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02238-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02238-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02238-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T10:02:58Z","timestamp":1661335378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02238-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2238"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02238-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"23 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}